Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital declines year over year
Q1 FY2026 change in working capital of $1.51M (cash outflow) fell 68.3% year over year, behind the -9.5% change in trailing-twelve-month change in working capital. Sequentially, it fell 60.2% from the prior quarter.
Context
- Change in working capital amounted to 14108.3% of revenue in FY2025, up 12884.5 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -68.3% toward the trailing-twelve-month pace of -9.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (9.22M) USD
- Year-over-year change
- -245.9%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.22M) | -245.9% |
| FY2024 | 2024-12-31 | (2.66M) | +74.0% |
| FY2023 | 2023-12-31 | (10.26M) | -151.7% |
| FY2022 | 2022-12-31 | 19.83M | -60.6% |
| FY2021 | 2021-12-31 | 50.35M | — |
Change in Working Capital vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 change in working capital of $5.96M is the 4th largest of the 10 companies compared; the peer median is $4.33M.
- Its year-over-year change of -9.5% is the 3rd highest of 10, against a peer median of -47.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $76.79M | -46.0% | — | 417.0% | |
| LTM Mar 2026 | $17.32M | -47.0% | +14.7% | 1509.8% | |
| LTM Mar 2026 | $13.46M | -148.1% | — | 24.6% | |
| LTM Mar 2026 | $5.96M | -9.5% | — | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $4.5M | +548.7% | — | — |
| LTM Mar 2026 | $4.33M | -45.5% | -52.4% | 68.6% | |
| LTM Mar 2026 | $4.12M | +8308.2% | -56.6% | 27.4% | |
| LTM Mar 2026 | $3.5M | -141.8% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $1.96M | -181.7% | -27.1% | 16.4% |
| LTM Mar 2026 | $1.39M | -106.1% | +4.3% | 1.1% | |
| Peer median (excluding INO) | $4.33M | -47.0% | -27.1% | 27.4% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| Deferred Income Tax | 0 | 4.03M | (32.05K) | 0 | 0 |
| Stock-Based Compensation | 26.34M | 22.56M | 11.07M | 6.6M | 3.76M |
| Change in Working Capital | 50.35M | 19.83M | (10.26M) | (2.66M) | (9.22M) |
| Accounts Receivables | 11.03M | (3.71M) | 9.33M | 1.21M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 26.14M | 32.61M | (45.99M) | (3.37M) | (6.42M) |
| Other Working Capital | 13.18M | (9.07M) | 26.4M | (504.04K) | (2.8M) |
| Other Non-Cash Items | 6.53M | 11.69M | 6.47M | (3.88M) | (1.21M) |
| Operating Cash Flow | (215.71M) | (216.22M) | (124.37M) | (104.08M) | (88.63M) |
| Capital Expenditures | (1.23M) | (969.15K) | (320.9K) | (487.83K) | (285.7K) |
| Acquisitions (Net) | 0 | (2M) | 6.22M | 0 | 0 |
| Purchases of Investments | (348.95M) | (248.53M) | (203.48M) | (54.14M) | (4.95M) |
| Sales of Investments | 174.84M | 361.08M | 284.93M | 158.64M | 19.27M |
| Other Investing Activities | 0 | 0 | 0 | 59.32K | 0 |
| Investing Cash Flow | (175.34M) | 109.59M | 87.36M | 104.07M | 14.04M |
| Debt Repayment | 0 | 0 | 0 | (16.42M) | 0 |
| Common Stock Issued | 209.44M | 82.96M | 5.46M | 68.31M | 53.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.06M | (1.11M) | (466.65K) | (420.8K) | (110.78K) |
| Financing Cash Flow | 211.5M | 81.84M | 5M | 51.48M | 53.05M |
| Effect of Forex Changes | (30.13K) | (25.56K) | (3.92K) | 32.4K | 0 |
| Net Change in Cash | (179.58M) | (24.81M) | (32.02M) | 51.5M | (21.54M) |
| Free Cash Flow | (216.94M) | (217.18M) | (124.69M) | (104.56M) | (88.92M) |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.